Your session is about to expire
← Back to Search
ARX788 for Solid Tumors
Study Summary
This trial will help find the best dose of a new cancer drug, ARX788, and assess how well it works against HER2 positive breast, gastric, and other solid tumors.
- Breast Cancer
- Gastric Neoplasm
- Solid Tumors
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 331 Patients • NCT02257567Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- The study is only open to people who are expected to live for at least 3 more months.You have had eye problems in the past or currently have an active eye infection.You have a history of unstable brain spread of cancer.You have not received any experimental or approved cancer treatment within 14 days before starting the study.You are expected to live for at least three more months.You have had an allergic reaction to any part of the drug ARX788.You have had heart failure, unstable chest pain, irregular heart rhythm, or other heart problems in the past year.
Frequently Asked Questions
Has ARX788 been officially sanctioned by the FDA?
"There is scant evidence of its safety and efficacy, so ARX788 received a score of 1."
In what areas is this research opportunity accessible?
"Currently, this medical trial is registering participants at 5 centres across the country. Those closest to you geographically include Cleveland, Santa Monica and Los Angeles, plus 2 other places. Choosing a nearby site minimizes travel demands should you decide to join us in our research effort."
Is enrollment in this study currently available?
"According to the clinicaltrials.gov database, this medical experiment has stopped recruiting patients for participation; it originally began on March 20th 2018 and was last edited November 3rd 2022. Nevertheless, there are 5153 other trials that remain open for enlistment at present."
What major goals are investigators hoping to accomplish through this trial?
"According to Ambrx, Inc., the main objective of this 36-month trial is to determine the frequency and severity of adverse events. Secondary objectives involve assessing PK characteristics such as ARX788 AUC, half-life from first infusion until end of study, and response rate based on RECIST 1.1 imaging assessment."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger